Institutional investors purchased a net $1.5 million shares of RGEN during the quarter ended September 2016 and now own 95.09% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
TIMESSQUARE CAPITAL MANAGEMENT L... Bought 1.4 Million shares of Repligen Corp
MARSHALL WACE LLP Bought 283.7 Thousand shares of Repligen Corp
KALMAR INVESTMENTS, INC. Bought 248.9 Thousand shares of Repligen Corp